Aclaris Therapeutics Raises $46.7 Million in Underwritten Offering
PUBLIC · ACRSOct 27, 2026
Amount Raised
$46.7 Million
Round Type
Post-IPO Equity
WayneHealthcare
Investors
Cantor Fitzgerald & Co.Piper Sandler & Co.Leerink Partners LLC
Description
Aclaris Therapeutics, Inc. has entered into an underwriting agreement to issue and sell common stock and pre-funded warrants in an underwritten offering. The estimated net proceeds from the offering are approximately $46.7 million. The closing of the offering is anticipated on October 28, 2026, subject to customary conditions.
Who to call at Aclaris Therapeutics, and when
A new round usually means Aclaris Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Aclaris Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Aclaris Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aclaris Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Aclaris Therapeutics
Location
Wayne, Pennsylvania, United States
About
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aclaris Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WayneHealthcare